Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cell type-specific regulatory programs that drive type 1 diabetes (T1D) in the pancreas are poorly understood. Here, we performed single-nucleus multiomics and spatial transcriptomics in up to 32 nondiabetic (ND), autoantibody-positive (AAB), and T1D pancreas donors. Genomic profiles from 853,005 cells mapped to 12 pancreatic cell types, including multiple exocrine subtypes. β, Acinar, and other cell types, and related cellular niches, had altered abundance and gene activity in T1D progression, including distinct pathways altered in AAB compared to T1D. We identified epigenomic drivers of gene activity in T1D and AAB which, combined with genetic association, revealed causal pathways of T1D risk including antigen presentation in β cells. Last, single-cell and spatial profiles together revealed widespread changes in cell-cell signaling in T1D including signals affecting β cell regulation. Overall, these results revealed drivers of T1D in the pancreas, which form the basis for therapeutic targets for disease prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/sciadv.ady0080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-cell multiome and spatial profiling reveals pancreas cell type-specific gene regulatory programs of type 1 diabetes progression.
Sci Adv
September 2025
Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Cell type-specific regulatory programs that drive type 1 diabetes (T1D) in the pancreas are poorly understood. Here, we performed single-nucleus multiomics and spatial transcriptomics in up to 32 nondiabetic (ND), autoantibody-positive (AAB), and T1D pancreas donors. Genomic profiles from 853,005 cells mapped to 12 pancreatic cell types, including multiple exocrine subtypes.
View Article and Find Full Text PDFTLR5 influences the development of type 1 diabetes.
BMJ Open Diabetes Res Care
September 2025
Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg Campus, Frederiksberg, Denmark.
Unlabelled: In mammalian and human life, it is important that the immune system defends against microorganisms. Although there is a huge overlap, innate cells are good against bacteria, whereas T cells are good against viruses, mainly because of antibody production via T helper and B lymphocytes. Toll-like receptor 5 (TLR5) is a regulator; when it is highly expressed, T cells are inhibited, and innate cells are favored.
View Article and Find Full Text PDFUnlabelled: Currently approved type 1 diabetes (T1D) immunotherapies broadly target T cells and delay but do not fully prevent diabetes development, highlighting the need for more selective targets. Anti-insulin germinal center B cells are uniquely able to present pathogenic insulin epitopes and drive anti-insulin T cells to adopt a T follicular helper fate. T cell expression of BCL6, a key transcriptional repressor in the germinal center response, is essential for spontaneous diabetes in non-obese diabetic (NOD) mice.
View Article and Find Full Text PDFProinflammatory Cytokines Mediate Pancreatic β-Cell-Specific Alterations to Golgi Integrity via iNOS-Dependent Mitochondrial Inhibition.
Diabetes
September 2025
Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA.
Unlabelled: Type 1 diabetes (T1D) is caused by the selective autoimmune ablation of pancreatic β-cells. Emerging evidence reveals β-cell secretory dysfunction arises early in T1D development and may contribute to diseases etiology; however, the underlying mechanisms are not well understood. Our data reveal that proinflammatory cytokines elicit a complex change in the β-cell's Golgi structure and function.
View Article and Find Full Text PDFImmune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling.
Front Immunol
September 2025
Chemical and Biological Engineering, Koc University, Istanbul, Türkiye.
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, resulting in lifelong insulin therapy that falls short of a true cure. Beta cell replacement therapies hold immense potential to restore natural insulin production, but they face significant hurdles such as immune rejection, limited donor availability, and long-term graft survival. In this review, we explore cutting-edge advances in genetic engineering, biomaterials, and machine learning approaches designed to overcome these barriers and enhance the clinical applicability of beta cell therapies.
View Article and Find Full Text PDF